By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK Read about our COVID-19 Response. Site Search Email Subscription Subscribe to Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Cerus Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Cerus Corporation to send you the requested Investor Email Alert updates. * Required Email Address * Mailing Lists * Press Releases Events Presentations SEC Filings SUBMIT For further information on how we protect your information, please refer to our Privacy Policy. Unsubscribe from Email Alerts To opt-out of investor email alerts, please enter your email address in the field below and you will be removed from all investor relations email alerts to which you are subscribed. After submitting your email, you will receive a confirmation email to the requested email address. You must click the confirmation link in order to complete your request to unsubscribe. You can elect to receive investor alerts at any time you would like. * Required Email Address * UNSUBSCRIBE Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2021 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc. Back to top About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. Powered By Q4 Inc. 5.56.0.1 (opens in new window) About Cerus